C ongestive heart failure (CHF) is a leading cause of morbidity and mortality in industrialized countries. Cachexia, characterized by severe loss of muscle mass, and exercise intolerance, manifested as fatigue and dyspnea during minimal physical activities, are important predictors of mortality in CHF. The progressive decline of exercise capacity results from multiple skeletal muscle abnormalities, including atrophy, impaired excitation-contraction coupling, mitochondrial dysfunction, and vascular rarefaction. [1] [2] [3] Oxidative stress due to excessive production of reactive oxygen species (ROS) or reduced antioxidant defenses has emerged as a central player in cardiac cachexia and is mechanistically linked to intracellular signaling, contractile protein function, and degradation. [3] [4] [5] [6] Although animal studies have shown the effectiveness of antioxidant supplements in treatment, clinical trials have limited successes, 7, 8 possibly because of lack of specificity to the target cells and subcellular environment leading to either poor efficacy or impairment of physiological signaling. It is critical to identify a viable approach to augment the endogenous antioxidant defense system to cope with this complicated clinical syndrome. secreted and has high affinity for sulfated polysaccharides, such as heparin and heparin sulfate, through its haprin-binding domain on the C-terminus. EcSOD may also be internalized by the cells that it binds through endocytosis. 9 Therefore, EcSOD may exert antioxidant function intracellularly and extracellularly in producing cells and target cells.
The expression of this antioxidant enzyme seems to be prone to suppression by pathological conditions, potentially underlying the cause of the diseases. For example, reduced EcSOD expression has been reported in many chronic diseases, including CHF. 10, 11 In terms of functionality, genetic deletion of the EcSOD gene exacerbates, [12] [13] [14] whereas transgenic overexpression attenuates the pathologies in mouse models of chronic diseases. 14, 15 These findings have clearly established the functional importance of EcSOD in protection against diseases caused by oxidative stress; however, its importance of skeletal muscle mass and function is unknown.
We have recently identified a nitric oxide (NO)-dependent antioxidant defense mechanism that underlies the resistance of oxidative muscles to catabolic wasting. 3, 16, 17 To ascertain the protective function of NO and to identify the antioxidant gene(s) that plays a major role in this protection, we first administered systemically an endogenous NO donor, S-nitrosoglutathione (GSNO), in a mouse model of catabolic muscle wasting induced by glucocorticoid, a hormone that is elevated in CHF and involved in muscle catabolism. 18 Our findings underscore the importance of NO-mediated induction of EcSOD expression in protection against catabolic muscle wasting. We then used 2 independent genetic approaches and showed that enhanced EcSOD expression in skeletal muscle ameliorates cardiac cachexia and exercise intolerance along with blunted oxidative stress, atrophy gene expression, mitochondrial loss, and microvascular abnormalities in a mouse model of CHF. We have, therefore, provided convincing evidence to support the effectiveness of enhancing EcSOD expression and antioxidant activity in protecting skeletal muscle structural and functional integrity under the condition of CHF.
Methods

Animals
Male wild-type (WT) mice (8 weeks old; C57BL/6J) were obtained commercially (Jackson Laboratory, Bar Harbor, ME) and housed in temperature-controlled (22°C) quarters with a 12/12 hour light/dark cycle and free access to water and normal chow (Harlan). A musclespecific EcSOD transgenic mouse line was generated at the University of Virginia Gene Targeting and Transgenic Facility. Briefly, RT-PCR was performed using mouse skeletal muscle RNA with forward primer 5ʹ-TGGATCCACCATGTTGGCCTTCTTGTTC-3ʹ and reverse primer 5ʹ-AGGTACCAGTGGTCTTGCACTCGCTCTC-3ʹ to obtain EcSOD cDNA (NM_011435). A Bam H1-Kpn I fragment (762 bp) of the coding region was then fused to a FLAG sequence followed by a stop codon in pTarget (Promega, Madison, WI) to create pEc-SOD. A 1.3-kb Hind III-Eco RI fragment of FLAG-tagged EcSOD was then inserted into pMCKhGHpolyA between a 4.8-kb mouse muscle creatine kinase (MCK) promoter and the human growth hormone polyadenylation site. 19 A linear Not I-Xho I fragment (6.7 kb) was isolated and used for pronuclear injection to generate transgenic mice (C57BL/6.SJL F1 background). We backcrossed the transgene onto pure C57BL/6J background (≥7 generations). To determine if enhanced EcSOD expression prevents CHF-induced muscle atrophy, MCK-EcSOD mice were crossbred with α-myosin heavy chain (α-MHC)-calsequestrin mice (CSQ; DBA background) 20 to generate double-transgenic MCK-EcSOD:α-MHC-CSQ mice (DTG). The WT littermates or littermates with only MCK-EcSOD allele (TG) were used as controls. Therefore, the mice used were of the same genetic background. To prevent negative impact of HF on embryonic development, the α-MHC-CSQ breeder mice were treated with β-blocker, metoprolol, in drinking water before and during breeding, 6 and the β-blocker was removed at birth such that none of the mice used in the studies received β-blocker after birth. Voluntary wheel running protocol is as described. 21 All animal protocols were approved by the University of Virginia Animal Care and Use Committee.
Genotyping PCR of tail DNA was performed using MCK transgenic forward primer, 5ʹ-GAC TGA GGG CAG GCT GTA AC-3ʹ; EcSOD intron forward primer, 5ʹ-GGG AGG TGG GAA GAG TTA GG-3ʹ; and EcSOD coding reverse primer, 5ʹ-CAC CTC CAT CGG GTT GTA GT-3ʹ. Exogenous EcSOD expression in adult skeletal muscle was confirmed by immunoblot as described. 6
Dexamethasone and GSNO Injections
Mice received daily injection of dexamethasone (25 mg/kg, intraperitoneally; Sigma, St Louis, MO) or normal saline with/without GSNO (2 mg/kg) twice a day for 7 days. 22 At 12 and 24 hours after the last injection of GSNO and dexamethasone, respectively, soleus, plantaris, tibialis anterior, gastrocnemius, extensor digitorum longus (EDL), and white vastus lateralis muscles were harvested and processed for further analyses.
Semiquantitative RT-PCR and Real-Time PCR
These analyses were performed for MAFbx/Atrogin-1, MuRF1, and Gapdh mRNAs in plantaris muscles as described. 23 Real-time PCR was performed using primers for MAFbox/Atrogin 1 and 18S rRNA from Applied Biosystems (Foster City, CA).
Immunoblot Analysis
Immunoblot analysis was performed as described 6 with the following primary antibodies: CuZnSOD (Abcam), MnSOD (Abcam), EcSOD (R&D, MN), peroxisome proliferator-activated receptor γ coactivator 1-α (PGC-1α; Chemicon/Millipore), cytochrome oxidase IV (Invitrogen), cytochrome C (Cell Signaling, Danvers, MA), malondialdehyde (Academy Biomedical Company, Inc, Houston, TX), and 4-hydroxynonenal (ab48506; Abcam). Hybridoma for antibodies against MHC I (BA-F8), MHC IIa (SC-71), and MHC IIb (BF-F3) were purchased from German Collection of Microorganisms and Cell Cultures. All the bands for analysis have been validated previously. 3, 6, 24 OxyBlot Protein Oxidative Detection Kit (Millipore) was used for immunblot detection of carbonylated proteins. Immunoblots were analyzed by Odyssey Infrared Imaging System (LI-COR Biosciences, NE) and quantified by Scion Image software.
Immunohistochemistry
Fresh frozen muscle sections (5 μm) were stained with rabbit anti-EcSOD (Sigma), and image acquisition and analysis of capillary density were performed as described. 3
Somatic Gene Transfer and Measurement of Myofiber Size
We performed electric pulse-mediated gene transfer by injecting DNA (15 μg of pGFP3 plus 50 μg of pEcSOD or pCI-neo) in tibialis anterior muscles as described. 24 Confocal microscopy (Fluoview 1000; Olympus) was performed to measure the fiber size of GFPpositive fibers (>100 fibers for each mouse) using ImageJ. 6
Treadmill Running Test
The test was performed as described. 3 Blood lactate level was measured before, at 40 minutes, and immediately after the test by Lactate Scout (SensLab, Leipzig, Germany).
Whole Body Tension Test
Whole body tension test was performed according to an established method 25 in a custom-designed device. Ten trials were performed with 10-second intervals for each mouse, and the mean value of the 5 peak readings was used for statistical analysis.
Magnetic Resonance Imaging
MRI was used to assess cardiac function as described. 26 
Electrocardiography
Electrocardiography was performed on conscious mice using the ECGenie (Mouse Specifics, Boston, MA). Mice were placed on the platform for 10 minutes to acclimate. Data with continuous recordings of >40 heart beats were used for analyses by using eMOUSE, a physiological waveform analysis platform (Mouse Specifics).
Whole-Mount Immunofluorescence
Flexor digitorum brevis muscles were immunolabeled for smooth muscle α-actin (IA4-Cy3; Sigma) and isolectin (IB4-Alexa647 or Alexa488; Invitrogen) as described. 27 
Statistics
The results are presented as mean±SE with each of the individual data points plotted. Comparisons between 2 groups were analyzed by the Wilcoxon rank-sum test. A 2-way ANOVA was used for comparisons across groups, and when appropriate, a post hoc test was used for detection of differences. When the data failed to meet the normality assumption, logarithmic transformation (base 10) was used before ANOVA. When the data failed to meet the equal variance assumption, a nonparametric test (Kruskal-Wallis) was used and, when appropriate, the Dunn post hoc analysis to detect difference across specific means. A P value <0.05 was required to report significance.
Results
Systemic Administration of GSNO Induces EcSOD Expression and Prevents Dexamethasone-Induced Muscle Wasting
We have recently shown that an NO-dependent antioxidant defense system may underlie the resistance of oxidative muscles to catabolic muscle wasting. 3, 6, 16 To determine whether NO donor is sufficient to provide protection in vivo and to identify the antioxidant gene(s) that is functionally involved, we performed daily injections of dexamethasone (25 mg/kg, intraperitoneally) with/without endogenous NO donor GSNO (2 mg/kg, intraperitoneally twice a day) in mice for 7 days. Dexamethasone injection led to a significant increase in lipid peroxidation in skeletal muscle as assessed by 4-hydroxynonenal immunoblot ( Figure SI in the Data Supplement). Dexamethasone injection caused a significant reduction of EcSOD protein expression (−29.7%; P<0.001), but not for CuZnSOD, MnSOD, or catalase ( Figure 1A) . GSNO alone induced a moderate increase of EcSOD (P<0.05) and completely prevented the reduction of EcSOD protein expression induced by dexamethasone ( Figure 1A ). Dexamethasone induced a significant increase of ubiquitin E3 ligase MAFbx/ Atrogin-1 mRNA (1.9-fold; P<0.05), which was completely blocked by GSNO ( Figure 1B ). No significant differences were detected for MuRF1 mRNA. Importantly, dexamethasone injection induced significant atrophy in fast-twitch, glycolytic EDL (-14.5%; P<0.001), tibialis anterior (-4.6%; P<0.05), gastrocnemius (-10.8%; P<0.001), and plantaris muscles (-9.5%; P<0.001), but not in slow-twitch, oxidative soleus muscle. Therefore, endogenous NO donor administration significantly attenuated muscle atrophy in all the fasttwitch, glycolytic muscles ( Figure 1C ).
EcSOD Is Highly Expressed in Oxidative Muscle, Induced by Endurance Exercise Training and Accumulates at Capillary Endothelial Cells
To determine which type(s) of muscle fibers expresses EcSOD, we used immunofluorescence. We found that EcSOD was expressed at a moderate level in most of the fibers in fast-twitch, glycolytic plantaris muscle (Figure 2A ). In contrast, EcSOD was highly expressed in most of the fibers in slow-twitch, oxidative soleus muscle with clear evidence of enrichment at capillary endothelial cells (Figure 2A , indicated by arrows). The specificity of immunofluorescence was confirmed both by negative staining without primary antibody (not shown) and by positive staining of aortic smooth muscle and bronchioles of the lung (Figure 2A ). Fiber type analysis revealed that EcSOD was primarily expressed by type IIa and IId/x myofibers ( Figure 2B ), whereas neither type IIb nor type I fibers expressed detectable levels of EcSOD. Furthermore, immunoblot analysis provided clear evidence that EcSOD is expressed more abundantly in slow-twitch, oxidative soleus muscle than fast-twitch, glycolytic white vastus lateralis muscle (P<0.05; Figure 2C ). Finally, voluntary running (4 weeks) induced EcSOD protein expression in plantaris muscle (+79.9%; P<0.01; Figure 2D ). Therefore, EcSOD expression in skeletal muscle is enhanced by contractile activities, which may underlie the protective effects of exercise training and oxidative phenotype. 3, 6 
Somatic Gene Transfer-Mediated EcSOD Overexpression in Adult Skeletal Muscle Protects Myofibers From Atrophy
Our finding that dexamethasone injection decreases EcSOD expression in atrophying muscle suggests that reduced EcSOD expression plays a role in catabolic wasting. Blocking the reduction of EcSOD expression along with the prevention of muscle atrophy by GSNO administration further supports this notion. To determine if enhanced EcSOD expression is sufficient to protect myofibers from catabolic wasting, we performed electric pulse-mediated gene transfer in fast-twitch, glycolytic tibialis anterior muscle. High levels of exogenous EcSOD expression were confirmed when compared with the contralateral control muscle (pCI-neo; Figure 3A) . Systemic administration of dexamethasone resulted in a leftward shift (reduction) of the fiber size histogram with a significant reduction of the mean cross-sectional area in pCI-neo-transfected myofibers (−14.5%; P<0.01), whereas myofibers transfected with EcSOD were protected from atrophy ( Figure 3B and 3C).
Muscle-Specific EcSOD Expression in Transgenic Mice Significantly Attenuates Muscle Wasting
To further ascertain the protective role of EcSOD in catabolic muscle wasting, we generated a transgenic mouse line with muscle-specific overexpression of EcSOD under the control of the MCK promoter ( Figure 4A , top left panel). We detected significantly greater EcSOD protein expression in skeletal muscles in MCK-EcSOD mice than in WT littermates ( Figure 4A , top right panel). The increases seemed to be more profound in plantaris and white vastus lateralis muscles than in soleus muscle. Immunofluorescence of EcSOD along with fiber typing analysis showed that exogenous EcSOD was highly expressed in type IIb fibers ( Figure 4A , bottom panel). These fiber type-specific expression patterns are consistent with the notion that the MCK promoter is more active in fast-twitch, glycolytic fibers. EcSOD also appeared to be enriched at endothelial cells ( Figure 4A , bottom panel by arrows). Consistent with findings presented in Figure 1 , dexamethasone injection induced muscle mass loss in WT mice by −27.5% for EDL (P<0.001), −19.5% for tibialis anterior (P<0.01), 19 .0% for gastrocnemius (P<0.001), and 14.7% for plantaris (P<0.001) muscles, but not in soleus muscle (Figure 4B ). More importantly, dexamethasone injection did not cause significant reduction in muscle mass in any of these muscles in MCK-EcSOD mice, suggesting that enhanced EcSOD expression is sufficient to protect fast-twitch, glycolytic fibers from catabolic wasting ( Figure 4B ). Protein expression of antioxidant enzymes (CuZnSOD, MnSOD, and catalase) and mitochondrial (cytochrome oxidase IV and cytochrome C) and contractile proteins (MHC I, IIa, and IIb) were not significantly different between MCK-EcSOD mice and WT littermates in these muscles ( Figure 4C ), suggesting that the protection in MCK-EcSOD mice was most likely because of enhanced antioxidant function, not adaptive responses induced by transgene overexpression. 
Muscle-Specific EcSOD Transgenic Mice Are Resistant to Cachexia and Exercise Intolerance Induced by CHF
Our previous studies 6, 16 and current findings (Figures 1, 3 , and 4) suggest that enhanced EcSOD expression is sufficient to preserve skeletal muscle mass and function under conditions of cachexia. We expected that MCK-EcSOD mice would be resistant to CHF in developing cachexia and exercise intolerance.
To this end, we generated MCK-EcSOD:α-MHC-CSQ doubletransgenic mice by crossbreeding. Although α-MHC-CSQ and MCK-EcSOD:α-MHC-CSQ double-transgenic mice had similar mortality, probably because of severe dilated cardiomyopathy ( Figure SII in the Data Supplement), a significant attenuation of cachexia (assessed by body weight) was observed in MCK-EcSOD:α-MHC-CSQ double-transgenic mice at 7 weeks of age compared with α-MHC-CSQ mice (P<0.01; Figure 5A ). Importantly, CHF-induced exercise intolerance as indicated by a dramatic reduction in treadmill running distance (P<0.001) was blunted in MCK-EcSOD:α-MHC-CSQ mice (P<0.001 versus CSQ; Figure 5B ). This functional protection was confirmed by blood lactate levels; all 4 groups of mice displayed increases in blood lactate, but the highest levels independent of time points were observed in α-MHC-CSQ mice (P<0.05 versus WT, TG, DTG; Figure 5C ). The area under curve of blood lactate for the first 40 minutes of the running test was significantly higher in α-MHC-CSQ mice compared with WT mice (P<0.01), which was blunted in MCK-EcSOD:α-MHC-CSQ mice (P<0.05 versus CSQ). Noninvasive whole body tension test showed that α-MHC-CSQ mice have a significantly reduced force production (39.9%; P<0.01) compared with WT mice ( Figure 5D ), which was also blunted in MCK-EcSOD:α-MHC-CSQ mice (P<0.05 versus CSQ).
Improved skeletal muscle function in MCK-EcSOD:α-MHC-CSQ mice could theoretically be a result of improved cardiac function by protection from overexpressed EcSOD redistributing to the heart. To test this possibility, we first performed immunoblot and semiquantitative RT-PCR and found significantly increased EcSOD protein in the heart without increased EcSOD mRNA ( Figure SIII in the Data Supplement) along with elevated EcSOD in the serum in MCK-EcSOD mice, suggesting that muscle EcSOD redistributed to the heart through the circulation. MCK-EcSOD:α-MHC-CSQ mice, however, developed the same degree of cardiac hypertrophy ( Figure 5E ) and reduction of ejection fraction as α-MHC-CSQ mice ( Figure 5F ). Electrocardiography showed significantly increased QRS intervals (Table) and decreased heart rate (P<0.01) in these mice to the same degree ( Figure 5G ). Therefore, reduced cachexia and improved muscle function in MCK-EcSOD:α-MHC-CSQ mice did not seem to be a result of improved cardiac function. We also crossbred MCK-EcSOD mice with a genetic model of amyotrophic lateral sclerosis, SOD1-G93A mice. SOD1-G93A mice harbor transgene expressing autosomal dominant fashion of a mutant form of CuZnSOD that results in amyotrophic lateral sclerosis-like motor neuron disease. SOD1-G93A and SOD1-93A:MCK-EcSOD mice had similar survival curve ( Figure SV in the Data Supplement) with significant reduction of body weight at 14 weeks of age and reduced muscle force production at 8 weeks of age ( Figure SV in the Data Supplement). Therefore, EcSOD did not provide protection for skeletal muscle when the insults were of motor neuron origin.
Muscle-Specific EcSOD Transgenic Mice Are Resistant to CHF in Developing Cachexia and Multiple Abnormalities
To obtain structural and biochemical evidence of EcSODmediated protection, we measured muscle mass and normalized by tibia length to minimize the effect of body weight reduction. CHF led to a significant loss of muscle mass in EDL (−38.4%; P<0.01), tibialis anterior (−37.3%; P<0.01), gastrocnemius (−42.3%; P<0.001), plantaris (−43.3%; P<0.01) but to a less degree in soleus (−28.7%; P<0.001) muscles in α-MHC-CSQ mice compared with WT littermates, which were significantly attenuated in MCK-EcSOD:α-MHC-CSQ mice ( Figure 6A ). Fiber size analyses showed that α-MHC-CSQ mice had significantly reduced IId/x/IIb fiber size (−42.8%; P<0.05; Figure 6B ), which was blunted by EcSOD overexpression (P<0.05 versus CSQ).
Consistent with our previous finding, 3 α-MHC-CSQ mice had significantly decreased capillary contacts in glycolytic type IId/x/IIb fibers (P<0.01), but not in oxidative type IIa fibers. The loss of capillarity was significantly attenuated in MCK-EcSOD:α-MHC-CSQ mice (P<0.05 versus CSQ; Figure 6C) . We also performed whole-mount immunofluorescence staining for CD31 and smooth muscle α-actin in flexor digitorum brevis muscle and measured the fractal dimension of microvessels (arterioles and venules), a measure of the number of branches and microvessels. There were no significant differences in fractal dimension among different groups ( Figure 6D ), suggesting that vascular rarefaction did not occur at the arteriole and venule levels in α-MHC-CSQ mice. α-MHC-CSQ mice are known to have reduced mitochondrial (cytochrome C, cytochrome oxidase IV) and PGC-1α protein expression indicative of mitochondrial dysfunction in fast-twitch, glycolytic muscles. 3, 6 Here, we showed that a preferentially reduced expression of these proteins in fasttwitch, glycolytic white vastus lateralis muscle was absent in MCK-EcSOD:α-MHC-CSQ mice ( Figure 6D ), suggesting that the overexpression of EcSOD is sufficient to block CHF-induced mitochondrial dysfunction in skeletal muscle. Consistently, CHF condition in α-MHC-CSQ mice did not cause any significant changes in myosin heavy chain protein isoforms, and EcSOD overexpression alone in MCK-EcSOD mice did not cause compensatory changes either. Real-time PCR analysis showed that α-MHC-CSQ mice had significantly elevated MAFbx/Atrogin-1 mRNA (P<0.001), which was significantly reduced in MCK-EcSOD:α-MHC-CSQ mice (P<0.05 versus CSQ; Figure 6F ). We did not detect significant differences of apoptosis assessed by TUNEL staining ( Figure SIV in the Data Supplement). Most importantly, we performed 3 different analyses to determine whether EcSOD overexpression had any significant impact on oxidative stress induced by CHF. We found that CHF (in α-MHC-CSQ mice) led to significantly elevated levels of oxidative stress markers, malondialdehyde and protein carbonyls, in fast-twitch, glycolytic white vastus lateralis muscle, which were significantly reduced in MCK-EcSOD:α-MHC-CSQ mice ( Figure 6G ( Figure SVI in the Data Supplement). These findings provide evidence for EcSOD function in protecting skeletal muscle from cardiac cachexia at molecular, biochemical, structural, and functional levels likely through its ectopic antioxidant function.
Table. Muscle-Specific Extracellular Superoxide Dismutase (EcSOD) Expression Does Not Provide Significant Protection Against Congestive Heart Failure in α-MHC-CSQ Mice as Assessed by Electrocardiography
Discussion
Studies with genetic and pharmacological interventions in cultured myocytes and intact skeletal muscles have provided ample evidence that intracellular antioxidant defenses are critical in maintaining normal redox state, muscle mass, and function. 28, 29 Here, we provide clear in vivo evidence that EcSOD expression in skeletal muscle is reduced under glucocorticoidism, a condition of many chronic diseases including CHF that is associated with increased oxidative stress, 30 muscle wasting, and loss of muscle function. 18 We showed that systemic administration of endogenous NO donor could attenuate skeletal muscle atrophy induced by dexamethasone in mice concurrent with a restoration of EcSOD expression. These findings suggest that NO-dependent EcSOD expression is important for muscle maintenance in vivo. We then used 2 independent genetic approaches and showed that myofibers with acquired EcSOD expression do not undergo significant atrophy on glucocorticoidism. Muscle-specific EcSOD transgenic mice are resistant to CHF, displaying significant protection against cachexia, exercise intolerance, and loss of mitochondria, rarefaction of microvasculature, and increased atrophy gene expression in skeletal muscle. Most importantly, we have shown evidence of reduced oxidative stress when ectopic EcSOD is overexpressed in a mouse model of cardiac cachexia. These findings provide, for the first time, unequivocal evidence that induced EcSOD expression protects myofibers from catabolic muscle wasting in vivo, suggesting that promoting EcSOD expression by augmenting NO bioavailability in skeletal muscle could be an effective intervention for CHF patients. NO plays an important signaling role in physiological and pathological processes. We have reported that injection of lipopolysaccharide, a major mediator of sepsis, induces greater NO production in slow-twitch, oxidative muscle than in fasttwitch, glycolytic muscle in mice. 3, 16 Because these oxidative muscles are resistant to catabolic muscle wasting under many disease conditions, the findings suggest that elevated NO production is protective. Our previous studies in cultured myocytes provided further evidence for a functional link between NO and antioxidant gene expression. 6, 16 Consistently, the data presented in this and previous studies 16, 31 showed robust induction of EcSOD expression when there is increased NO bioavailability, suggesting that NO-induced EcSOD expression in skeletal muscle may contribute significantly to the protection associated with oxidative phenotype.
The functional importance of EcSOD has been shown by its reduced expression associated with various chronic diseases 10, 11 and by the fact that genetic deletion and overexpression of EcSOD leads to exacerbation and protection against pathological changes, respectively, in animal models of diseases. [12] [13] [14] [15] Glucocorticoids are used as therapeutic agents because of their potent anti-inflammatory and immunosuppressive functions; however, high dose and long-term use of glucocorticoids causes muscle atrophy. 22, 32 Previous studies and our current data support an increased oxidative stress induced by dexamethasone in skeletal muscle with direct evidence of increased free radicals. 22, 33 Oxidative stress may promote catabolic wasting and loss of muscle function through cell signaling, impairment of contractile protein, and promotion of protein degradation. 4, 5, 34, 35 Here, we provide new evidence for reduced EcSOD protein expression in catabolic muscle wasting and the functional importance of NO-mediated EcSOD expression in protection against catabolic wasting.
A key question is how EcSOD protects skeletal muscle from atrophy. Because EcSOD is the only isoform of SOD that is secreted to the extracellular space, one straightforward explanation is that elevated extracellular ROS, which could be scavenged by EcSOD, plays an important role in cachexia and exercise intolerance. Several pathological steps might be relevant here. First, extracellular ROS could cause endothelial cell apoptosis, 36 leading to vascular rarefaction, an important feature of cardiac cachexia. Vascular rarefaction not only impairs microcirculation and tissue perfusion but also exacerbates muscle wasting due to hypoxia. Second, superoxide reacts readily with NO to reduce NO bioavailability, 37 impairing exerciseinduced increase of blood flow and contributing to exercise intolerance. Finally, extracellular ROS-mediated intracellular ROS production and signaling 38 may play an important role in catabolic muscle wasting. Enhanced EcSOD expression could provide protection through ≥1 of these mechanisms. Studies showing protective effects of antioxidants when applied directly to cultured cells seem to be consistent with EcSOD function in scavenging extracellular superoxide; however, in light of the findings that EcSOD can be internalized by cells that it binds, 9 elevated intracellular EcSOD in myofibers or other cells in skeletal muscle may also contribute to the protection.
The protective role of EcSOD is likely mediated by its antioxidant properties. Based on the evidence of reduced oxidative stress markers and atrogene expression in glycolytic muscles ( Figure 6F and 6G), we think that transgenic overexpression of EcSOD in skeletal muscle exerts its protective function by counteracting oxidative stress induced by CHF. The findings of muscle mass, mitochondrial protein, and vascular rarefaction are all extremely consistent with this notion. Future studies should focus on elucidating the necessity of EcSOD expression in skeletal muscle in maintaining muscle mass and function under catabolic wasting conditions. It has been shown that EcSOD expression by smooth muscle can be enhanced by exercise training in an NO-dependent manner, 31 and EcSOD mRNA is increased by acute exercise in skeletal muscle. 39 It has been shown recently that exercise training protects oxidative stress and proteasome-dependent protein degradation in CHF-induced skeletal muscle atrophy. 40 An unanswered question is which effecter gene(s) is responsible for the enhanced antioxidant function induced by exercise training. Our findings suggest EcSOD could be an important player. We show here that exercise training promotes EcSOD expression in skeletal muscle (Figure 2) , and that enhanced EcSOD expression is sufficient to provide protection against cardiac cachexia and exercise intolerance.
Another issue is whether enhanced expression of EcSOD from skeletal muscle redistributes to the extracellular space of the heart leading to improved cardiac function and preventing cachexia. EcSOD-mediated protection against cardiac toxicity has been shown by Kliment et al 41 where EcSOD global knockout mice showed exacerbated cardiac dysfunction, myocardial apoptosis, and fibrosis after doxorubicin injection. We have previously shown that adenovirus-mediated gene transfer of EcSOD in the heart elicits protective effects on cardiac function after myocardial infarction in rabbits. 42 In this study, although forced expression of EcSOD from skeletal muscle redistributed to the heart ( Figure SIII in the Data Supplement), it did not improve cardiac function and prevent premature death. These findings allowed us to focus on the impact of ectopic EcSOD expression in skeletal muscle on catabolic muscle wasting without confounding factors of EcSOD overexpression in impeding HF. Because abnormal calcium and G-protein coupling signaling are caused by calsequestrin overexpression from within cardiac myocytes, 43 the negative findings of EcSOD effects in the heart suggest that elevated EcSOD in the heart of α-MHC-CSQ mouse is not enough to deal with such a severe CHF condition or with pathogenesis of CHF of an intracellular origin.
Previous findings support the view that exercise intolerance in CHF is a result of skeletal muscle abnormalities although the failing heart is the primary cause. [44] [45] [46] Consistent with this scenario, our findings suggest that the improved skeletal muscle outcomes in MKC-EcSOD:α-MHC-CSQ mice were not because of improved cardiac function. Our measurements of baseline heart function, heart weight, skeletal muscle weight, and survival curve collectively suggest that EcSOD overexpression had a negligible impact on the progression of HF induced by cardiac overexpression of calsequestrin in our model. On the contrary, skeletal muscle abnormalities are significantly blocked/attenuated along with improved contractile function and exercise capacity. We, therefore, think that the effects of elevated EcSOD in the heart on cardiac function, if present, likely has a minor impact on exercise capacity. It would be interesting to ascertain whether muscle overexpression of EcSOD is protective against other types of CHF.
The concept that exercise intolerance in CHF results from multiple skeletal muscle abnormalities will be instrumental to developing effective interventions. We have previously shown that CHF leads to preferential vascular rarefaction in fast-twitch, glycolytic muscle fibers in CHF, 3 and that skeletal muscles with overexpression of PGC-1α have significantly elevated EcSOD expression, less muscle atrophy, and vascular rarefaction under the condition of CHF. 6 Here, we again detected vascular rarefaction in fast-twitch, glycolytic fibers in α-MHC-CSQ mice, which was significantly attenuated by EcSOD overexpression. Because EcSOD accumulates at the endothelium, EcSOD may also protect endothelial cells against oxidative stress-induced apoptosis. We have also previously shown that skeletal muscles undergoing catabolic wasting lose mitochondria with reduced expression of PGC-1α and increased oxidative stress, 3, 6 which may contribute directly to exercise intolerance. The fact that EcSOD overexpression prevents the reduction of mitochondrial and PGC-1α proteins strongly suggests that ROS induced by CHF induces pathological events in muscle. This could explain why enhanced EcSOD expression in skeletal muscle can provide potent protection and lead to preserved exercise capacity in MCK-EcSOD:α-MHC-CSQ mice. Previous studies have also linked oxidative stress to catabolic muscle wasting with evidence for enhanced ubiquitin-proteasome 16, [47] [48] [49] and autophagy-lysosome systems. 22, 50 The link of oxidative stress to autophagy, particularly mitochondrial autophagy (mitophagy), may underlie the loss of mitochondria in CHF. A vicious cycle between oxidative stress and mitochondrial dysfunction could be critical for the development of cardiac cachexia and exercise intolerance.
Finally, we have previously shown that overexpression of PGC-1α in skeletal muscle leads to increased inducible NO synthase, endothelial NO synthase, EcSOD, MnSOD, CuZnSOD, and catalase expression in skeletal muscle along with increased FOXO and Akt phosphorylation. 6 We postulated that PGC-1α enhances FOXO and Akt phosphorylation in parallel with enhanced NO-antioxidant defense axis. Our current findings, consistent with this postulation, suggest that increased NO can directly stimulate EcSOD in skeletal muscle providing protection. It is of note that increased NO alone without overexpression of PGC-1α only stimulates EcSOD, but not other antioxidant enzymes. This NO inducibility of EcSOD expression helped us to focus on the function of this important, yet understudied, antioxidant enzyme in protection against muscle wasting.
In summary, we obtained novel findings to support that NO-mediated protection against catabolic muscle wasting is associated with enhanced EcSOD protein expression. Genetic interventions with forced expression of EcSOD in skeletal muscles significantly attenuate muscle atrophy. Importantly, muscle-specific EcSOD transgenic mice are resistant to CHF in developing cachexia and exercise intolerance with significant protection against oxidative stress, atrophic gene expression, and loss of mitochondria and microvasculature. We now propose a model where enhanced skeletal muscle EcSOD expression prevents endothelial and muscular abnormalities in cachexia and exercise intolerance likely because of the maintenance of redox homeostasis (Figure 7) . The findings pave , which in turn cause abnormalities in muscle vasculature (endothelial dysfunction and apoptosis) and muscle fibers (atrophy and mitochondrial dysfunction). These abnormalities in skeletal muscle underscore the development of exercise intolerance presumably by impairing blood supply and muscle contractile and metabolic functions. EcSOD in extracellular space in skeletal muscle may provide the first line of defense against the excessive production of extracellular free radicals under the condition of CHF, ultimately preserving muscle function.
the way for targeting NO-dependent EcSOD expression for the prevention and treatment of cardiac cachexia.
